(Q40626160)

22 September 2017

1 reference

title

Long-term depot antipsychotics. A risk-benefit assessment (English)

1 reference

22 September 2017

T R Barnes

1

1 reference

PubMed ID

7917075

22 September 2017

D A Curson

series ordinal

2

1 reference

22 September 2017

1 June 1994

1 reference

22 September 2017

1 reference

22 September 2017

10

1 reference

22 September 2017

6

1 reference

22 September 2017

464-479

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-199410060-00005

22 September 2017

0 references

cites work

Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses

1 reference

12 December 2020

Depot pipotiazine 1970-1982: a review

1 reference

12 December 2020

Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry.

1 reference

12 December 2020

Chlorpromazine plasma levels, adverse effects, and tobacco smoking: case report

1 reference

12 December 2020

The contribution of fluphenazine enanthate and decanoate in the prevention of readmission of schizophrenic patients

1 reference

12 December 2020

Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year

1 reference

12 December 2020

A Controlled Trial of Fluphenazine Enanthate in Hospitalized Chronic Schizophrenics

1 reference

12 December 2020

Prevention of Recidivism of Schizophrenics Treated with Fluphenazine Enanthate

1 reference

12 December 2020

Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention.

1 reference

12 December 2020

Acute extrapyramidal reactions with fluphenazine hydrochloride and fluphenazine decanoate

1 reference

12 December 2020

A double-blind, controlled clinical trial of haloperidol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia

1 reference

12 December 2020

A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia

1 reference

12 December 2020

Use of the Social Behaviour Assessment Schedule (SBAS) in a trial of maintenance antipsychotic therapy in schizophrenic outpatients: Pimozide versus fluphenazine

1 reference

12 December 2020

Fluphenazine enanthate in sesame oil, a depot preparation

1 reference

12 December 2020

Prospective study of course of illness in schizophrenia: Part II. Prediction of outcome

1 reference

12 December 2020

The nature and prevalence of depression in chronic schizophrenic in-patients

1 reference

12 December 2020

Technique for injecting long-acting neuroleptics

1 reference

12 December 2020

Flupenthixol decanoate--in treatment of out-patients

1 reference

12 December 2020

Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride

1 reference

12 December 2020

Tardive dyskinesia in schizophrenic outpatients: prevalence and significant variables

1 reference

12 December 2020

Depressive syndromes in the year following onset of a first schizophrenic illness*

1 reference

12 December 2020

'Akinetic Depression' in Schizophrenia

1 reference

12 December 2020

Pharmacokinetic studies in volunteers of intravenous and oral cis (Z)-flupentixol and intramuscular cis (Z)-flupentixol decanoate in Viscoleo.

1 reference

12 December 2020

Anticholinergic drug abuse: a common problem?

1 reference

12 December 2020

'Revealed' Depression and Drug Treatment for Schizophrenia

1 reference

12 December 2020

Tardive dyskinesia in psychiatric outpatients: a study of prevalence and association with demographic, clinical, and drug history variables.

1 reference

12 December 2020

Compliance in the long-term treatment of schizophrenia

1 reference

12 December 2020

Comparative efficacy of long-acting depot and oral neuroleptic medications in preventing schizophrenic recidivism.

1 reference

12 December 2020

Suicide in Chronic Schizophrenia

1 reference

12 December 2020

Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients

1 reference

12 December 2020

Studies on serum protein binding of haloperidol

1 reference

12 December 2020

Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches

1 reference

12 December 2020

Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate

1 reference

12 December 2020

Changing from oral to depot fluphenazine

1 reference

12 December 2020

A Clinical Guide to Antipsychotic Drugs

1 reference

12 December 2020

Drug variables in the etiology of tardive dyskinesia application of discriminant function analysis

1 reference

12 December 2020

Abscesses following prolonged intramuscular administration of perphenazine enantate

1 reference

12 December 2020

Serum concentrations of the isomers of clopenthixol and a metabolite in patients given cis(Z)-clopenthixol decanoate in viscoleo

1 reference

12 December 2020

The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences

1 reference

12 December 2020

Injection site reactions after intramuscular administration of haloperidol decanoate 100 mg/mL.

1 reference

12 December 2020

Pharmacokinetics of haloperidol decanoate. A 2-year follow-up

1 reference

12 December 2020

Intramuscular or intralipomatous injections?

1 reference

12 December 2020

A mirror image Out-patient study at a depot phenothiazine clinic

1 reference

12 December 2020

The Scottish First Episode Schizophrenia Study. II. Treatment: pimozide versus flupenthixol. The Scottish Schizophrenia Research Group

1 reference

12 December 2020

Differences in the nature of relapse and subsequent inpatient course between medication-compliant and noncompliant schizophrenic patients.

1 reference

12 December 2020

Depression and the reintegration phase of acute schizophrenia

1 reference

12 December 2020

Treatment of schizophrenia

1 reference

12 December 2020

Tardive dyskinesia and current dose of neuroleptic drugs

1 reference

12 December 2020

The Nithsdale schizophrenia surveys. IX: Akathisia, parkinsonism, tardive dyskinesia and plasma neuroleptic levels

1 reference

12 December 2020

Depot fluphenazine: risk/benefit ratio

1 reference

12 December 2020

Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome

1 reference

12 December 2020

Controlled Trial of Depot Fluphenazine in Out-patient Schizophrenics

1 reference

12 December 2020

Guidelines for the dosage of neuroleptics. I: Chlorpromazine equivalents of orally administered neuroleptics.

1 reference

12 December 2020

Drug-use evaluation programs for psychotropic medications.

1 reference

12 December 2020

Practical considerations in the use of depot neuroleptics for the treatment of schizophrenia

1 reference

12 December 2020

Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis

1 reference

12 December 2020

Probable toxic necrosis after prolonged fluspirilene administration

1 reference

12 December 2020

Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia

1 reference

12 December 2020

Studies of depressive symptoms in schizophrenia

1 reference

12 December 2020

The natural course of schizophrenia and effective maintenance drug treatment

1 reference

12 December 2020

Depressive changes after fluphenazine treatment.

1 reference

12 December 2020

The problem of post-psychotic schizophrenic depressions and their pharmacological induction. Long-term studies with fluspirilene and penfluridol and single-blind trial with fluphenazine-decanoate and flupenthixol-decanoate

1 reference

12 December 2020

The suicide rate in schizophrenia

1 reference

12 December 2020

Drug therapy in renal failure: dosing guidelines for adults. Part II: sedatives, hypnotics, and tranquilizers; cardiovascular, antihypertensive, and diuretic agents; miscellaneous agents

1 reference

12 December 2020

Clinical pharmacokinetics of the depot antipsychotics

1 reference

12 December 2020

Haloperidol decanoate and flupenthixol decanoate in schizophrenia. A long-term double-blind cross-over comparison.

1 reference

12 December 2020

Clinical relevance of the effect of hepatic disease on drug disposition

1 reference

12 December 2020

Chemotherapy with neuroleptics. Clinical and pharmacokinetic aspects with a particular view to depot preparations

1 reference

12 December 2020

Akinesia and postpsychotic depression: a difficult differential diagnosis

1 reference

12 December 2020

Long-acting oral vs injectable antipsychotic drugs in schizophrenics: a one-year double-blind comparison in multiple episode schizophrenics

1 reference

12 December 2020

Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia

1 reference

12 December 2020

Variation in oro-facial tardive dyskinesia during depot antipsychotic drug treatment

1 reference

12 December 2020

Protein Binding and Kinetics of Drugs in Liver Diseases

1 reference

12 December 2020

A long-term follow-up of fluphenazine enanthate treatment

1 reference

12 December 2020

Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial I. Course of illness, stability of diagnosis, and the role of a special maintenance clinic

1 reference

12 December 2020

Drug prescribing for schizophrenic out-patients on depot injections. Repeat surveys over 18 years

1 reference

12 December 2020

Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. IV. Serum levels and clinical outcome

1 reference

12 December 2020

Community psychiatry in a London borough. An eleven-year analysis of a socio-medical service for psychiatric illness

1 reference

12 December 2020

Factors related to tardive dyskinesia

1 reference

12 December 2020

The bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patients

1 reference

12 December 2020

Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates

1 reference

12 December 2020

Low dose maintenance medication for schizophrenia.

1 reference

12 December 2020

Haloperidol plasma levels and clinical response: a therapeutic window relationship

1 reference

12 December 2020

Depressive and Extrapyramidal Symptoms and Clinical Effects: A Trial of Fluphenazine versus Flupenthixol in Maintenance of Schizophrenic Out-patients

1 reference

12 December 2020

Depot Phenothiazine Treatment in Acute Psychosis: A Sequential Comparative Clinical Study

1 reference

12 December 2020

Review of haloperidol blood level and clinical response: looking through the window

1 reference

12 December 2020

Surreptitious noncompliance with oral fluphenazine in a voluntary inpatient population

1 reference

12 December 2020

Drug history and tardive dyskinesia

1 reference

12 December 2020

The depot fluphenazines: a reappraisal after 10 years' clinical experience

1 reference

12 December 2020

Comparison of antipsychotic depot injections in the maintenance treatment of schizophrenia

1 reference

12 December 2020

Drug defaulting by patients on long-acting phenothiazines

1 reference

12 December 2020

A comparative study of fluphenazine enanthate and trifluoperazine in chronic schizophrenic patients.

1 reference

12 December 2020

Fluphenazine decanoate trial in chronic in-patient schizophrenics failing to absorb oral chlorpromazine

1 reference

12 December 2020

A CONTROLLED STUDY OF FLUPHENAZINE ENANTHATE IN CHRONIC SCHIZOPHRENIC PATIENTS

1 reference

12 December 2020

Severe Depressive Mood Changes Following Slow-release Intramuscular Fluphenazine Injection

1 reference

12 December 2020

Very high dose fluphenazine decanoate: a controlled trial in chronic schizophrenia

1 reference

12 December 2020

[Pharmacokinetics of pipothiazine palmitate, after intramuscular administration in schizophrenic patients]

1 reference

12 December 2020

Fluphenazine enanthate and fluphenazine decanoate: intramuscular injection and esterification as requirements for slow - release characteristics in dogs

1 reference

12 December 2020

10.2165/00002018-199410060-00005

Identifiers

DOI

1 reference

PubMed ID

7917075

Dimensions Publication ID

22 September 2017

0 references

1 reference

PubMed ID

7917075